October 1, 2020 by Jason Wertheimer LinkedIn The time is now: Autoimmune and inflammatory diseases, meet regulatory T-cell therapy Learn More
September 30, 2020 by Jason Wertheimer Endpoints News Sonoma Bio named as one of most promising startups in biotech by Endpoints News Learn More
September 30, 2020 by Jason Wertheimer Endpoints News Jeffrey Bluestone recruits a trio of biopharma vets to the startup team at Sonoma — while adding $30M to the launch round Learn More
June 23, 2020 by Jason Wertheimer Nature Foxp3: a genetic foundation for regulatory T cell differentiation and function Learn More
February 7, 2020 by Jason Wertheimer Stat Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases Learn More
February 7, 2020 by Jason Wertheimer Biospace Parker Institute CEO Jeffrey Bluestone Steps Down to Launch Sonoma Biotherapeutics Learn More